Literature DB >> 22487996

Mild therapeutic hypothermia in cardiogenic shock syndrome.

Carsten Zobel1, Christoph Adler, Anna Kranz, Catherine Seck, Roman Pfister, Martin Hellmich, Matthias Kochanek, Hannes Reuter.   

Abstract

OBJECTIVE: Mortality in patients with cardiogenic shock after out-of-hospital cardiac arrest remains high despite advances in resuscitation and early revascularization strategies. Recent studies suggest a reduced mortality in survivors of cardiac arrest subjected to mild therapeutic hypothermia, but the underlying mechanisms are not yet clear. Because positive hemodynamic effects of mild therapeutic hypothermia have been suggested, we aimed at testing the hypothesis that patients in cardiogenic shock might benefit from mild therapeutic hypothermia.
METHODS: Hemodynamic effects of mild therapeutic hypothermia in 20 consecutive patients admitted in cardiogenic shock after successful resuscitation from out-of-hospital cardiac arrest were investigated. A historic normothermic control group was matched (one-to-one) by means of a propensity score. Patients were cooled to 33°C for 24 hrs using an endovascular cooling device and hemodynamic variables were continuously recorded by means of pulse contour analysis. Cardiac performance was determined by echocardiography.
RESULTS: Mild therapeutic hypothermia induced a significant decrease in heart rate from 74 to 64 beats per minute. Despite the reduction in heart rate, cardiac index remained unchanged under mild therapeutic hypothermia likely due to an increase in ejection fraction from 43 ± 4% to 55 ± 4%. Mean arterial pressure increased rapidly from 75 ± 2 mm Hg to 84 ± 3 mm Hg (p = .001) upon induction of hypothermia paralleled by an initial increase in systemic vascular resistance. Accordingly, patients with mild therapeutic hypothermia required lower cumulative doses of vasopressors and inotropes.
CONCLUSIONS: We conclude that in cardiogenic shock mild therapeutic hypothermia provides circulatory support and an increase in systemic vascular resistance that leads to reduced vasopressor use and may result in lower oxygen consumption. These findings suggest that mild therapeutic hypothermia could be a therapeutic option in hemodynamically unstable patients independent of cardiac arrest and further randomized clinical studies are needed.

Entities:  

Mesh:

Year:  2012        PMID: 22487996     DOI: 10.1097/CCM.0b013e318246b820

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  26 in total

1.  Higher mean arterial pressure with or without vasoactive agents is associated with increased survival and better neurological outcomes in comatose survivors of cardiac arrest.

Authors:  Marie E Beylin; Sarah M Perman; Benjamin S Abella; Marion Leary; Frances S Shofer; Anne V Grossestreuer; David F Gaieski
Journal:  Intensive Care Med       Date:  2013-08-31       Impact factor: 17.440

2.  Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients.

Authors:  Valentine Léopold; Etienne Gayat; Romain Pirracchio; Jindrich Spinar; Jiri Parenica; Tuukka Tarvasmäki; Johan Lassus; Veli-Pekka Harjola; Sébastien Champion; Faiez Zannad; Serafina Valente; Philip Urban; Horng-Ruey Chua; Rinaldo Bellomo; Batric Popovic; Dagmar M Ouweneel; José P S Henriques; Gregor Simonis; Bruno Lévy; Antoine Kimmoun; Philippe Gaudard; Mir Babar Basir; Andrej Markota; Christoph Adler; Hannes Reuter; Alexandre Mebazaa; Tahar Chouihed
Journal:  Intensive Care Med       Date:  2018-06-01       Impact factor: 17.440

3.  Higher achieved mean arterial pressure during therapeutic hypothermia is not associated with neurologically intact survival following cardiac arrest.

Authors:  Michael N Young; Ryan D Hollenbeck; Jeremy S Pollock; Jennifer L Giuseffi; Li Wang; Frank E Harrell; John A McPherson
Journal:  Resuscitation       Date:  2014-12-22       Impact factor: 5.262

4.  The association of targeted temperature management at 33 and 36 °C with outcome in patients with moderate shock on admission after out-of-hospital cardiac arrest: a post hoc analysis of the Target Temperature Management trial.

Authors:  Martin Annborn; John Bro-Jeppesen; Niklas Nielsen; Susann Ullén; Jesper Kjaergaard; Christian Hassager; Michael Wanscher; Jan Hovdenes; Tommaso Pellis; Paolo Pelosi; Matt P Wise; Tobias Cronberg; David Erlinge; Hans Friberg
Journal:  Intensive Care Med       Date:  2014-07-08       Impact factor: 17.440

5.  Pre-arrest hypothermia improved cardiac function of rats by ameliorating the myocardial mitochondrial injury after cardiac arrest.

Authors:  Yuanzheng Lu; Xiaoyun Zeng; Xiaoli Jing; Meixian Yin; Mms Mary P Chang; Hongyan Wei; Yan Yang; Xiaoxing Liao; Gang Dai; Chunlin Hu
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-17

6.  [Mild therapeutic hypothermia in cardiogenic shock : Retrospective analysis of 80 patients with preclinical cardiac arrest due to cardiac causes].

Authors:  C Adler; R Pfister; S Baldus; H Reuter
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-12-17       Impact factor: 0.840

Review 7.  Clinical significance of lactate in acute cardiac patients.

Authors:  Chiara Lazzeri; Serafina Valente; Marco Chiostri; Gian Franco Gensini
Journal:  World J Cardiol       Date:  2015-08-26

8.  Normothermic cardiopulmonary bypass increases cerebral tissue oxygenation during combined valve surgery: a single-centre, randomized trial.

Authors:  Andrey I Lenkin; Viktor I Zaharov; Pavel I Lenkin; Alexey A Smetkin; Lars J Bjertnaes; Mikhail Y Kirov
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-13

9.  Myocardial dysfunction after out-of-hospital cardiac arrest: predictors and prognostic implications.

Authors:  Yuan Yao; Nicholas James Johnson; Sarah Muirhead Perman; Vimal Ramjee; Anne Victoria Grossestreuer; David Foster Gaieski
Journal:  Intern Emerg Med       Date:  2017-10-05       Impact factor: 3.397

Review 10.  Cardiac index during therapeutic hypothermia: which target value is optimal?

Authors:  Raphaël Giraud; Nils Siegenthaler; Karim Bendjelid
Journal:  Crit Care       Date:  2013-03-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.